Vir Biotechnology, Inc.(VIR)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

VIR Vir Biotechnology, Inc.

交易中 02-10 10:45:23 EST

7.45

+0.17

+2.27%

最高7.47	最低7.16	成交量16.59万
今开7.25	昨收7.28	日振幅4.26%
总市值10.36亿	流通市值7.04亿	总股本1.39亿
成交额121.17万	换手率0.18%	流通股本9,455万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"VIR","market":"US","secType":"STK","nameCN":"Vir Biotechnology, Inc.","latestPrice":7.445,"timestamp":1770738322078,"preClose":7.28,"halted":0,"volume":165921,"delay":0,"changeRate":0.022664835164835168,"floatShares":94554590,"shares":139125032,"eps":-3.622804,"marketStatus":"交易中","change":0.165,"latestTime":"02-10 10:45:23 EST","open":7.25,"high":7.47,"low":7.16,"amount":1211702.645769,"amplitude":0.042582,"askPrice":7.45,"askSize":600,"bidPrice":7.44,"bidSize":161,"shortable":3,"etf":0,"ttmEps":-3.622804,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1770757200000},"marketStatusCode":2,"adr":0,"listingDate":1570766400000,"exchange":"NASDAQ","adjPreClose":7.28,"preHourTrading":{"tag":"盘前","latestPrice":7.4,"preClose":7.28,"latestTime":"08:46 EST","volume":2,"amount":14.8,"timestamp":1770731207994,"change":0.12,"changeRate":0.016484,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":7.28,"preClose":7.28,"latestTime":"19:11 EST","volume":301409,"amount":2194252.12,"timestamp":1770682267589,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.590421,"impliedVol":0.9215,"impliedVolPercentile":0.741},"requestUrl":"/m/hq/s/VIR","defaultTab":"news","newsList":[{"id":"1173071595","title":"Vir Biotechnology公司公布二期Solstice试验积极更新数据：Tobevibart与Elebsiran联合疗法耐受性良好","url":"https://stock-news.laohu8.com/highlight/detail?id=1173071595","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173071595?lang=zh_cn&edition=full","pubTime":"2026-01-12 21:08","pubTimestamp":1768223300,"startTime":"0","endTime":"0","summary":"Vir Biotechnology, Inc.最新发布的二期Solstice试验更新数据显示，Tobevibart与Elebsiran的联合用药方案展现出优异的安全性特征。该结果表明，这一创新组合疗法在受试者中耐受度良好，未出现重大不良反应。\n此次数据更新进一步巩固了该联合疗法的临床前景，为后续研发提供了有力支持。研究人员指出，良好的耐受性是推进三期临床试验的关键基础，也为潜在的患者群体带来新的希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","BK4139","BK4585","VIR","BK4535"],"gpt_icon":0},{"id":"1136024377","title":"Vir Biotechnology公布慢性丁型肝炎与肿瘤项目最新进展，展望2026年临床里程碑","url":"https://stock-news.laohu8.com/highlight/detail?id=1136024377","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1136024377?lang=zh_cn&edition=full","pubTime":"2026-01-12 21:02","pubTimestamp":1768222967,"startTime":"0","endTime":"0","summary":"Vir Biotechnology, Inc.（以下简称\"Vir Biotechnology\"）近日就其慢性丁型肝炎治疗项目及肿瘤研发管线的最新动态进行了通报，同时披露了计划于2026年达成的重要临床里程碑。该公司在传染病与肿瘤领域的前沿研究持续引发行业关注，其创新疗法的开发进度将为患者提供新的治疗希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","BK4585","BK4568","BK4139","VIR"],"gpt_icon":0},{"id":"1191239464","title":"Vir Biotechnology - 在交易完成时将收到5500万欧元的初始补偿款，并将获得4.95亿欧元的临床、监管及销售里程碑款项","url":"https://stock-news.laohu8.com/highlight/detail?id=1191239464","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1191239464?lang=zh_cn&edition=full","pubTime":"2025-12-17 05:19","pubTimestamp":1765919965,"startTime":"0","endTime":"0","summary":"Vir Biotechnology - 在交易完成时将收到5500万欧元的初始补偿款，并将获得4.95亿欧元的临床、监管及销售里程碑款项","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4568","BK4585","BK4535","VIR"],"gpt_icon":0},{"id":"1121272875","title":"Vir Biotechnology预计当前现金、现金等价物及投资将延续至2027年第四季度","url":"https://stock-news.laohu8.com/highlight/detail?id=1121272875","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121272875?lang=zh_cn&edition=full","pubTime":"2025-12-17 05:19","pubTimestamp":1765919953,"startTime":"0","endTime":"0","summary":"Vir Biotechnology预计当前现金、现金等价物及投资将延续至2027年第四季度。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4535","VIR","BK4568","BK4585"],"gpt_icon":0},{"id":"1178858356","title":"Vir Biotechnology向Norgine授予慢性乙型肝炎德尔塔治疗候选药物在欧洲、澳大利亚和新西兰的独家商业许可，并达成全球成本分担协议以支持持续的Eclipse临床开发计划","url":"https://stock-news.laohu8.com/highlight/detail?id=1178858356","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178858356?lang=zh_cn&edition=full","pubTime":"2025-12-17 05:06","pubTimestamp":1765919195,"startTime":"0","endTime":"0","summary":"Vir Biotechnology向Norgine授予慢性乙型肝炎德尔塔治疗候选药物在欧洲、澳大利亚和新西兰的独家商业许可，并达成全球成本分担协议以支持持续的Eclipse临床开发计划。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4535","BK4139","VIR","BK4568"],"gpt_icon":0},{"id":"1152383992","title":"Vir Biotechnology宣布Eclipse 1三期试验的患者招募完成","url":"https://stock-news.laohu8.com/highlight/detail?id=1152383992","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1152383992?lang=zh_cn&edition=full","pubTime":"2025-11-03 21:01","pubTimestamp":1762174905,"startTime":"0","endTime":"0","summary":"Vir Biotechnology宣布Eclipse 1三期试验的患者招募完成，该试验旨在治疗慢性乙型肝炎δ。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","VIR","BK4535","BK4585","BK4139"],"gpt_icon":0},{"id":"1178018455","title":"Vir Biotechnology将在2025年11月5日发布企业更新及2025年第三季度财务业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=1178018455","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178018455?lang=zh_cn&edition=full","pubTime":"2025-10-23 04:06","pubTimestamp":1761163572,"startTime":"0","endTime":"0","summary":"Vir Biotechnology将在2025年11月5日发布企业更新及2025年第三季度财务业绩。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4568","VIR","BK4585","BK4535","BK4139"],"gpt_icon":0},{"id":"1199143749","title":"Vir Biotechnology宣布PSMA靶向Pro-Xten®双掩蔽T细胞接合器Vir-5500联合雄激素受体通路抑制剂治疗转移性前列腺癌的1期试验第3部分首位患者开始给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1199143749","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1199143749?lang=zh_cn&edition=full","pubTime":"2025-10-10 04:07","pubTimestamp":1760040448,"startTime":"0","endTime":"0","summary":"Vir Biotechnology宣布，其PSMA靶向Pro-Xten®双掩蔽T细胞接合器Vir-5500联合雄激素受体通路抑制剂治疗转移性前列腺癌的1期试验第3部分已完成首位患者给药。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4535","VIR","BK4585","BK4568"],"gpt_icon":0},{"id":"1138663622","title":"Vir Biotechnology, Inc.：美国银行全球研究将评级从中性上调至买入，目标价从12美元上调至14美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1138663622","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1138663622?lang=zh_cn&edition=full","pubTime":"2025-08-27 19:14","pubTimestamp":1756293249,"startTime":"0","endTime":"0","summary":"美国银行全球研究将Vir Biotechnology, Inc.的投资评级从中性上调至买入，同时将目标价格从12美元上调至14美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","BK4139","VIR","BK4568","BK4585"],"gpt_icon":0},{"id":"2518766872","title":"Vir Biotechnology, Inc.盘中异动 急速跳水5.01%报7.56美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518766872","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518766872?lang=zh_cn&edition=full","pubTime":"2025-03-10 22:46","pubTimestamp":1741617967,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日22时46分，Vir Biotechnology, Inc.股票出现异动，股价快速跳水5.01%。Vir Biotechnology, Inc.股票所在的生物技术行业中，整体跌幅为0.03%。其相关个股中，Checkpoint Therapeutics, Inc.、Mineralys Therapeutics, Inc.、Trevi Therapeutics, Inc.涨幅较大，Biodexa Pharmaceuticals Plc、Scisparc Ltd.、Aeon Biopharma, Inc.较为活跃，换手率分别为3490.39%、768.51%、666.04%，振幅较大的相关个股有Scisparc Ltd.、Dogwood Therapeutics, Inc.、Biodexa Pharmaceuticals Plc，振幅分别为45.34%、41.36%、40.33%。Vir Biotechnology, Inc.公司简介：Vir Biotechnology Inc 是一家免疫学公司，专注于结合尖端技术治疗和预防严重传染病和其他严重疾病，包括病毒相关疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031022460798a2af6e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025031022460798a2af6e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4535","BK4139","VIR","BK4568","BK4585"],"gpt_icon":0},{"id":"2517348985","title":"Vir Biotechnology, Inc.盘中异动 下午盘快速上涨5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517348985","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517348985?lang=zh_cn&edition=full","pubTime":"2025-03-05 04:23","pubTimestamp":1741119820,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日04时23分，Vir Biotechnology, Inc.股票出现波动，股价大幅拉升5.04%。Vir Biotechnology, Inc.股票所在的生物技术行业中，整体涨幅为0.27%。Vir Biotechnology, Inc.公司简介：Vir Biotechnology Inc 是一家免疫学公司，专注于结合尖端技术治疗和预防严重传染病和其他严重疾病，包括病毒相关疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305042340a25f66de&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305042340a25f66de&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","BK4568","VIR","BK4139","BK4535"],"gpt_icon":0},{"id":"2516077652","title":"Vir Biotechnology, Inc.盘中异动 股价大跌5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516077652","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516077652?lang=zh_cn&edition=full","pubTime":"2025-03-04 02:52","pubTimestamp":1741027951,"startTime":"0","endTime":"0","summary":"北京时间2025年03月04日02时52分，Vir Biotechnology, Inc.股票出现异动，股价急速下挫5.01%。Vir Biotechnology, Inc.股票所在的生物技术行业中，整体涨幅为0.59%。其相关个股中，Bioxcel Therapeutics, Inc.、Abpro Holdings Inc C/Wts 12/11/2029 、Radiopharm Theranostics Limited涨幅较大，Bioxcel Therapeutics, Inc.、Allarity Therapeutics, Inc.、Entero Therapeutics Inc.较为活跃，换手率分别为4444.65%、200.45%、179.81%，振幅较大的相关个股有Bioxcel Therapeutics, Inc.、Radiopharm Theranostics Limited、Entero Therapeutics Inc.，振幅分别为206.20%、119.50%、70.53%。Vir Biotechnology, Inc.公司简介：Vir Biotechnology Inc 是一家免疫学公司，专注于结合尖端技术治疗和预防严重传染病和其他严重疾病，包括病毒相关疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304025231abe67d4a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304025231abe67d4a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["VIR","BK4568","BK4139","BK4585","BK4535"],"gpt_icon":0},{"id":"2516480135","title":"Vir Biotechnology, Inc.2024财年实现净利润-5.22亿美元，同比增加15.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2516480135","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516480135?lang=zh_cn&edition=full","pubTime":"2025-03-03 00:01","pubTimestamp":1740931287,"startTime":"0","endTime":"0","summary":"3月3日，Vir Biotechnology, Inc.公布财报，公告显示公司2024财年净利润为-5.22亿美元，同比增加15.12%；其中营业收入为74.21百万美元，同比减少13.89%，每股基本收益为-3.83美元。机构评级：截至2025年3月3日，当前有8家机构对Vir Biotechnology, Inc.目标价做出预测，其中目标均价为32.00美元，其中最低目标价为14.00美元，最高目标价为110.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303000214abe4acf8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250303000214abe4acf8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["VIR"],"gpt_icon":0},{"id":"2516307997","title":"巴克莱：维持Vir Biotechnology(VIR.US)评级，由增持调整至增持评级, 目标价由26.00美元调整至31.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2516307997","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2516307997?lang=zh_cn&edition=full","pubTime":"2025-03-01 06:03","pubTimestamp":1740780193,"startTime":"0","endTime":"0","summary":"巴克莱：维持Vir Biotechnology(VIR.US)评级，由增持调整至增持评级, 目标价由26.00美元调整至31.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/01060348470365.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["VIR"],"gpt_icon":0},{"id":"2514373228","title":"HC Wainwright & Co.：重申Vir Biotechnology(VIR.US)评级，由买入调整至买入评级, 目标价由110.00美元调整至110.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2514373228","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514373228?lang=zh_cn&edition=full","pubTime":"2025-02-28 23:13","pubTimestamp":1740755582,"startTime":"0","endTime":"0","summary":"HC Wainwright & Co.：重申Vir Biotechnology(VIR.US)评级，由买入调整至买入评级, 目标价由110.00美元调整至110.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/28231348467203.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["VIR"],"gpt_icon":0},{"id":"2514385741","title":"Vir Biotechnology, Inc.盘中异动 急速拉升5.98%报9.75美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514385741","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514385741?lang=zh_cn&edition=full","pubTime":"2025-02-27 22:31","pubTimestamp":1740666662,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日22时31分，Vir Biotechnology, Inc.股票出现波动，股价急速上涨5.98%。Vir Biotechnology, Inc.股票所在的生物技术行业中，整体涨幅为0.06%。Vir Biotechnology, Inc.公司简介：Vir Biotechnology Inc 是一家免疫学公司，专注于结合尖端技术治疗和预防严重传染病和其他严重疾病，包括病毒相关疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022722310298950fe8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022722310298950fe8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4568","VIR","BK4585","BK4535"],"gpt_icon":0},{"id":"1100651160","title":"Vir Biotechnology第四季度每股收益$(0.76)优于预期$(0.87)，销售额$12.37M优于预期$8.14M","url":"https://stock-news.laohu8.com/highlight/detail?id=1100651160","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1100651160?lang=zh_cn&edition=full","pubTime":"2025-02-27 05:19","pubTimestamp":1740604750,"startTime":"0","endTime":"0","summary":"Vir Biotechnology 报告季度每股亏损$，优于分析师普遍预期的$，增长了12.64%。与去年同期的销售额$16.79M相比，减少了26.29%。以上内容来自Benzinga Earnings专栏，原文如下：Vir Biotechnology  reported quarterly losses of $ per share which beat the analyst consensus estimate of $ by 12.64 percent. This is a 11.63 percent increase over losses of $ per share from the same period last year.  The company reported quarterly sales of $12.37 million which beat the analyst consensus estimate of $8.14 million by 52.01 percent.  This is a 26.29 percent decrease over s","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Vir Biotechnology第四季度每股收益$(0.76)优于预期$(0.87)，销售额$12.37M优于预期$8.14M","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VIR"],"gpt_icon":0},{"id":"2514043922","title":"Vir Biotechnology, Inc.盘中异动 下午盘急速下跌5.12%报8.99美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514043922","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2514043922?lang=zh_cn&edition=full","pubTime":"2025-02-26 03:14","pubTimestamp":1740510894,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日03时14分，Vir Biotechnology, Inc.股票出现异动，股价大幅下跌5.12%。Vir Biotechnology, Inc.股票所在的生物技术行业中，整体跌幅为0.16%。Vir Biotechnology, Inc.公司简介：Vir Biotechnology Inc 是一家免疫学公司，专注于结合尖端技术治疗和预防严重传染病和其他严重疾病，包括病毒相关疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226031454a253c714&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226031454a253c714&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4568","VIR","BK4585","BK4535","BK4139"],"gpt_icon":0},{"id":"2511757920","title":"Vir Biotechnology, Inc.盘中异动 股价大涨5.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2511757920","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2511757920?lang=zh_cn&edition=full","pubTime":"2025-02-14 02:57","pubTimestamp":1739473057,"startTime":"0","endTime":"0","summary":"北京时间2025年02月14日02时57分，Vir Biotechnology, Inc.股票出现波动，股价快速上涨5.05%。Vir Biotechnology, Inc.股票所在的生物技术行业中，整体涨幅为0.86%。其相关个股中，Moleculin Biotech, Inc.、Edesa Biotech, Inc.、Dominari Holdings Inc.涨幅较大，Edesa Biotech, Inc.、Moleculin Biotech, Inc.、Tc Biopharm  Plc较为活跃，换手率分别为3157.01%、1848.00%、1224.21%，振幅较大的相关个股有Moleculin Biotech, Inc.、Edesa Biotech, Inc.、Immatics N V C/Wts 01/07/2025 ，振幅分别为733.31%、95.15%、92.30%。Vir Biotechnology, Inc.公司简介：Vir Biotechnology Inc 是一家免疫学公司，专注于结合尖端技术治疗和预防严重传染病和其他严重疾病，包括病毒相关疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502140257379621ef23&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502140257379621ef23&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4568","BK4535","VIR","BK4585"],"gpt_icon":0},{"id":"2510333111","title":"Vir Biotechnology, Inc.盘中异动 早盘快速下挫5.01%","url":"https://stock-news.laohu8.com/highlight/detail?id=2510333111","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510333111?lang=zh_cn&edition=full","pubTime":"2025-02-11 23:13","pubTimestamp":1739286814,"startTime":"0","endTime":"0","summary":"北京时间2025年02月11日23时13分，Vir Biotechnology, Inc.股票出现波动，股价快速跳水5.01%。Vir Biotechnology, Inc.股票所在的生物技术行业中，整体跌幅为1.53%。其相关个股中，Ocean Biomedical, Inc.、Dominari Holdings Inc.、Ocean Biomedical Inc C/Wts 14/02/2028 涨幅较大，Lipella Pharmaceuticals Inc.、Ocean Biomedical, Inc.、Dominari Holdings Inc.较为活跃，换手率分别为2539.13%、822.30%、338.44%，振幅较大的相关个股有Dominari Holdings Inc.、Ocean Biomedical, Inc.、In8Bio, Inc.，振幅分别为52.11%、43.92%、37.99%。Vir Biotechnology, Inc.公司简介：Vir Biotechnology Inc 是一家免疫学公司，专注于结合尖端技术治疗和预防严重传染病和其他严重疾病，包括病毒相关疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211231334abcb0fa0&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250211231334abcb0fa0&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4535","BK4568","BK4139","BK4585","VIR"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.vir.bio","stockEarnings":[{"period":"1week","weight":-0.0558},{"period":"1month","weight":0.2444},{"period":"3month","weight":0.275},{"period":"6month","weight":0.593},{"period":"1year","weight":-0.2602},{"period":"ytd","weight":0.2073}],"compareEarnings":[{"period":"1week","weight":-0.0021},{"period":"1month","weight":-0.0002},{"period":"3month","weight":0.016},{"period":"6month","weight":0.0761},{"period":"1year","weight":0.1551},{"period":"ytd","weight":0.0176}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Vir Biotechnology, Inc.于2016年4月7日根据特拉华州法律注册成立。该公司是一家免疫学公司，专注于结合前沿技术来治疗和预防严重传染病和其他严重疾病，包括病毒相关疾病。该公司的目标是通过两种基本方式实现这一目标——第一，通过开发强大的抗体疗法，第二，通过基于T细胞的病毒载体平台在体内产生独特的T细胞反应。","yearOnYearQuotes":[{"month":1,"riseRate":0.714286,"avgChangeRate":0.442895},{"month":2,"riseRate":0.285714,"avgChangeRate":0.02898},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.121524},{"month":4,"riseRate":0.166667,"avgChangeRate":-0.08783},{"month":5,"riseRate":0.666667,"avgChangeRate":0.058008},{"month":6,"riseRate":0.5,"avgChangeRate":0.020036},{"month":7,"riseRate":0.666667,"avgChangeRate":-0.044477},{"month":8,"riseRate":0.166667,"avgChangeRate":-0.0277},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.115495},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.03118},{"month":11,"riseRate":0.857143,"avgChangeRate":0.105555},{"month":12,"riseRate":0.285714,"avgChangeRate":-0.058058}],"exchange":"NASDAQ","name":"Vir Biotechnology, Inc.","nameEN":"Vir Biotechnology, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Vir Biotechnology, Inc.(VIR)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Vir Biotechnology, Inc.(VIR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Vir Biotechnology, Inc.,VIR,Vir Biotechnology, Inc.股票,Vir Biotechnology, Inc.股票老虎,Vir Biotechnology, Inc.股票老虎国际,Vir Biotechnology, Inc.行情,Vir Biotechnology, Inc.股票行情,Vir Biotechnology, Inc.股价,Vir Biotechnology, Inc.股市,Vir Biotechnology, Inc.股票价格,Vir Biotechnology, Inc.股票交易,Vir Biotechnology, Inc.股票购买,Vir Biotechnology, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Vir Biotechnology, Inc.(VIR)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Vir Biotechnology, Inc.(VIR)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}